🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
547,09 USD
Máx. histórico
558,88
7 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,11%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+0,85%
Cierre anterior
542,50
Rango de hoy
531,53 – 548,76
Volumen hoy
1.271.214
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 35,21 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 5 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/05/2006 | 34,94 | 35,73 | 34,63 | 35,59 | +1,63% | 3,15% | 817.800 |
| 03/05/2006 | 34,27 | 35,36 | 34,23 | 35,02 | +1,48% | 3,30% | 1.542.500 |
| 02/05/2006 | 35,60 | 35,65 | 34,24 | 34,51 | -3,20% | 3,96% | 1.590.300 |
| 01/05/2006 | 37,25 | 37,45 | 35,32 | 35,65 | -1,98% | 5,72% | 1.736.000 |
| 28/04/2006 | 35,65 | 36,75 | 35,62 | 36,37 | +1,14% | 3,17% | 1.115.500 |
| 27/04/2006 | 34,71 | 36,49 | 34,52 | 35,96 | +3,27% | 5,68% | 2.607.200 |
| 26/04/2006 | 35,78 | 35,97 | 33,60 | 34,82 | -7,15% | 6,62% | 4.025.100 |
| 25/04/2006 | 38,50 | 38,50 | 36,68 | 37,50 | -2,27% | 4,73% | 1.268.500 |
| 24/04/2006 | 38,91 | 39,00 | 37,36 | 38,37 | -2,04% | 4,21% | 1.447.400 |
| 21/04/2006 | 39,70 | 39,96 | 38,50 | 39,17 | -0,23% | 3,68% | 1.515.000 |
| 20/04/2006 | 39,35 | 40,00 | 38,90 | 39,26 | -0,61% | 2,80% | 1.900.500 |
| 19/04/2006 | 37,50 | 39,57 | 37,30 | 39,50 | +5,95% | 6,05% | 3.396.700 |
| 18/04/2006 | 35,57 | 37,48 | 35,57 | 37,28 | +5,10% | 5,37% | 1.527.500 |
| 17/04/2006 | 35,80 | 36,25 | 35,20 | 35,47 | -0,81% | 2,93% | 1.332.600 |
| 13/04/2006 | 35,02 | 36,21 | 34,76 | 35,76 | +1,79% | 4,14% | 1.196.300 |
| 12/04/2006 | 34,10 | 35,60 | 34,00 | 35,13 | +7,43% | 4,69% | 2.749.400 |
| 11/04/2006 | 33,72 | 34,06 | 32,52 | 32,70 | -3,02% | 4,57% | 1.790.900 |
| 10/04/2006 | 32,65 | 34,74 | 32,52 | 33,72 | +4,36% | 6,80% | 3.317.300 |
| 07/04/2006 | 33,81 | 33,85 | 31,10 | 32,31 | -4,35% | 8,13% | 3.578.500 |
| 06/04/2006 | 36,43 | 36,43 | 33,39 | 33,78 | -7,22% | 8,34% | 2.646.800 |
| 05/04/2006 | 36,30 | 36,87 | 35,80 | 36,41 | +0,08% | 2,95% | 926.900 |
| 04/04/2006 | 35,81 | 36,58 | 35,50 | 36,38 | +1,48% | 3,02% | 1.246.700 |
| 03/04/2006 | 36,64 | 36,98 | 35,60 | 35,85 | -2,02% | 3,77% | 1.348.900 |
| 31/03/2006 | 35,20 | 36,60 | 35,13 | 36,59 | +3,63% | 4,18% | 1.739.600 |
| 30/03/2006 | 35,87 | 36,43 | 34,81 | 35,31 | -1,62% | 4,52% | 1.243.500 |
| 29/03/2006 | 34,86 | 36,50 | 34,72 | 35,89 | +2,78% | 5,11% | 1.171.300 |
| 28/03/2006 | 35,36 | 35,56 | 34,68 | 34,92 | -1,80% | 2,49% | 1.126.500 |
| 27/03/2006 | 36,45 | 36,65 | 35,45 | 35,56 | -2,44% | 3,29% | 1.113.800 |
| 24/03/2006 | 36,11 | 37,04 | 36,00 | 36,45 | +1,11% | 2,88% | 1.312.800 |
| 23/03/2006 | 37,68 | 37,83 | 35,64 | 36,05 | -4,76% | 5,81% | 1.938.800 |